BIO2013: The Afterglow Edition
As we were making our way back home from Chicago (on delayed flights, of course), several things struck us about BIO2013. We've talked about BIO in the past.…
Menu
ExcipientFest 2013
Now that we're back from BIO2013, we have to leave again! We'll be at ExcipientFest 2013 in Baltimore for a few days. We'll be meeting with several Exhibitors,…
A blockbuster on $1 a day pricing?
Yesterday, North Carolina-based Pozen gave a detailed Investor Update, focused on PA32540, a "Coordinated-Delivery Tablet Containing Enteric-Coated Aspirin and Immediate-RElease Omeprazole." Information on the company's pipeline is available…
FDA is right…and wrong
Today's issue of FiercePharma covered two interesting FDA decisions (or non- decisions, if you prefer). The first involves the FDA's decision not to approve generic versions of Purdue's Oxycontin:…
Getting the Most out of BIO
Rob Wright has a really good article on preparing for BIO. In fact, it's applicable for just about any major conference or convention. You can read the entire…
No incentive to Indian pharma to innovate
Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India's pharmaceutical companies should be focused on R&D of medicines that will help the people…
Signal, Noise, and Clinical Trial Results
At Lacerta Bio, we've been reading the fascinating book, The Signal and The Noise by Nate Silver. The book is a terrific review of how and why forecasts often fail,…